According to a statement put out by Pfizer and BioNTech, they have jointly "requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech Vaccine (BNT162b2) to expand the use in adolescents 12 to 15 years of age."
Axios reports that the Pfizer BioNTech vaccine was found to be 100 percent effective in children in this age group, and that a trial has begun on children between 6 months and 11 years old.
Including younger people in the EUA would hasten the United States' vaccine rollout, and put the country one step closer to herd immunity.
Powered by StructureCMS™ Comments
Join and support independent free thinkers!
We’re independent and can’t be cancelled. The establishment media is increasingly dedicated to divisive cancel culture, corporate wokeism, and political correctness, all while covering up corruption from the corridors of power. The need for fact-based journalism and thoughtful analysis has never been greater. When you support The Post Millennial, you support freedom of the press at a time when it's under direct attack. Join the ranks of independent, free thinkers by supporting us today for as little as $1.
Remind me next month
To find out what personal data we collect and how we use it, please visit our Privacy Policy
Comments